ERBB2 and breast neoplasm: Based on the SYCP2 mRNA data from a large number of tumors, we found that the mRNA levels of SYCP2 in breast tumors do not significantly correlate with tumor stages (T1-T4), pathological stages (Stage I-IV), lymph node status (N0-N3), and Her2 levels (Supplementary Fig. 7D).